Please assess the completion status of the following clinical trial:

Trial Title: Study of AggreGuide A-100 (ADP) Assay

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has a history of cardiovascular disease OR~* Subject has 2 or more cardiac risk factors:~  * Smoking~ * Hypertension~ * Hyperlipidemia~ * Family History of Heart Disease~ * Post-menopausal female~ * Diabetes~ * Obesity (BMI \> 30)~ * Sedentary lifestyle~Exclusion Criteria:~Taken nonsteroidal anti-inflammatory drugs (NSAIDs) drugs, anti-platelet drugs or anticoagulant drugs within the past seven (7) days, over age 75, under 60 kg body weight, in the last trimester of pregnancy or breastfeeding, with a diagnosed history of: stroke or transient ischemic attacks, or other thromboembolic disease, anemia, thrombocytopenia, uncontrolled hypertension,platelet disorders,hemophilia or other bleeding disorder, gastrointestinal disease, severe renal disease, expect to engage in contact sports, scheduled for elective surgery, have a medical history as determined by the Investigator that would pose safety concerns, or possess contraindications for any of the study medications.

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: 74 Years
- Healthy Volunteers: t

Study Arms:
- Clopidogrel (Type: EXPERIMENTAL): Platelet function test before and after administration of P2Y12 inhibitor antiplatelet therapy after ASA 81 mg.~Loading dose day 1. Maintenance dose over subsequent 7 days.
- Prasugrel (Type: EXPERIMENTAL): Platelet function test before and after administration of P2Y12 inhibitor antiplatelet therapy after ASA 81 mg.~Loading dose day 1. Maintenance dose over subsequent 7 days.
- Ticagrelor (Type: EXPERIMENTAL): Platelet function test before and after administration of P2Y12 inhibitor antiplatelet therapy after ASA 81 mg.~Loading dose day 1. Maintenance dose over subsequent 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).